

# Cigarette smoking and depression comorbidity: systematic review and proposed theoretical model

Amanda R. Mathew<sup>1</sup>, Lee Hogarth<sup>2</sup>, Adam M. Leventhal<sup>3</sup>, Jessica W. Cook<sup>4,5</sup> & Brian Hitsman<sup>1</sup>

Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA,<sup>1</sup> School of Psychology, University of Exeter, Exeter, UK,<sup>2</sup> Departments of Preventive Medicine and Psychology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA,<sup>3</sup> University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA<sup>4</sup> and William S. Middleton Memorial Veterans Hospital, Madison, WI, USA<sup>5</sup>

## ABSTRACT

**Background and Aims** Despite decades of research on co-occurring smoking and depression, cessation rates remain consistently lower for depressed smokers than for smokers in the general population, highlighting the need for theory-driven models of smoking and depression. This paper provides a systematic review with a particular focus upon psychological states that disproportionately motivate smoking in depression, and frame an incentive learning theory account of smoking-depression co-occurrence. **Methods** We searched PubMed, Scopus, PsychINFO and CINAHL to December 2014, which yielded 852 papers. Using pre-established eligibility criteria, we identified papers focused on clinical issues and motivational mechanisms underlying smoking in established, adult smokers (i.e. maintenance, quit attempts and cessation/relapse) with elevated symptoms of depression. Two reviewers determined independently whether papers met review criteria. We included 297 papers in qualitative synthesis. **Results** Our review identified three primary mechanisms that underlie persistent smoking among depressed smokers: low positive affect, high negative affect and cognitive impairment. We propose a novel application of incentive learning theory which posits that depressed smokers experience greater increases in the expected value of smoking in the face of these three motivational states, which promotes goal-directed choice of smoking behavior over alternative actions. **Conclusions** The incentive learning theory accounts for current evidence on how depression primes smoking behavior and provides a unique framework for conceptualizing psychological mechanisms of smoking maintenance among depressed smokers. Treatment should focus upon correcting adverse internal states and beliefs about the high value of smoking in those states to improve cessation outcomes for depressed smokers.

**Keywords** Depression, nicotine dependence, review, smoking, smoking cessation, treatment.

Correspondence to: Amanda R. Mathew, Northwestern University Feinberg School of Medicine, Department of Preventive Medicine, 680 North Lake Shore Drive, Suite 1400, Chicago, IL 60611, USA. E-mail: amanda.mathew@northwestern.edu

Submitted 22 January 2016; 29 April 2016; final version accepted 5 September 2016

## INTRODUCTION

Individuals with depression are more likely to smoke, smoke more cigarettes per day and are less likely to quit smoking successfully than individuals without depression, and this health disparity is an important clinical and public health concern. Recent epidemiological data show that the smoking rate for clinically depressed individuals is approximately twice the rate in the general population [1–6]. Further, smokers with depression report greater nicotine withdrawal symptoms [7,8], due in part probably to greater nicotine dependence among depressed versus non-depressed smokers [9–12]. Although depressed smokers endorse levels of motivation to quit that are

similar to, or even higher than, smokers in the general population [13–15] and attempt to quit at similar rates [16], odds of successful abstinence at 1 month are 30–50% lower for those with current depression and elevated depressive symptoms [16].

As smoking prevalence continues to decline in the general population, those with mental illness are over-represented increasingly among smokers and constitute an important tobacco use disparity group [17]. Those with mental illness die up to 25 years earlier than those in the general population, due largely to chronic illnesses associated with smoking (e.g. cardiovascular disease [18–20]). Given that smoking cessation improves both mental [21–26] and physical health outcomes [27],

even among smokers with chronic health conditions, development of smoking cessation interventions targeted to those with various forms of mental illness (i.e. mood and anxiety disorders, substance use disorders, serious mental illness) are greatly needed. Herein, we focus our review on continuous depressive symptomatology [28–30], ranging from subsyndromal levels of depression to clinical disorders (i.e. current or past diagnosis of major depression).

Although promising cessation treatments exist (e.g. [31]), no treatment has been shown to attenuate fully the elevated relapse risk associated with depression, and further innovations in treatment development are needed. One major limitation to advances in treatment of comorbid smoking–depression has been a lack of comprehensive theories of the psychology of nicotine dependence and depression. Identifying the psychological mechanisms that underlie smoking persistence among those with elevated depressive symptoms is critical for (1) a comprehensive characterization of the causal connection between depression and smoking and (2) developing innovative, theory-based and effective treatment strategies which target these psychological mechanisms specifically in depressed smokers.

This systematic review provides an update of the current state of evidence on the topic of co-occurring smoking and depression and proposes a novel application of incentive learning theory to conceptualize smoking persistence among depressed smokers. As detailed below, the incentive learning account has gained considerable empirical support in the study of drug dependence [32–40], and offers a unique lens through which to view the clinical problem of smoking and depression. In particular, incentive learning theory proposes that specific states drive goal-directed selection of smoking behavior over alternate choices for depressed smokers. We believe that the incentive learning theory accounts for current evidence on how depression primes smoking and identifies novel psychological targets to optimize smoking cessation treatment for depressed smokers.

## MATERIALS AND METHODS

### Data sources and searches

We searched the PubMed, Scopus, PsycINFO and CINAHL databases to December 2014, using Medical Subject Headings or Major Concept search terms when available. We combined smoking-related (i.e. smoking, tobacco, nicotine, smoking cessation, tobacco use, tobacco use disorder, tobacco use cessation) and depression-related terms (i.e. depression, depressive, major depression). Search delimiters were ‘adult’, ‘human’ and ‘English language’. We also performed manual searches of reference lists of pertinent papers.

### Study eligibility

Two authors reviewed abstracts and full-text publications independently. Inclusion criteria stipulated that studies examine clinical issues relevant to established, adult smokers (age  $\geq 18$  years), such as causes and correlates of smoking maintenance, willingness to quit and cessation/relapse among established smokers, rather than smoking initiation or progression to regular smoking. The review included both current/past major depression and elevated depressive symptoms. Studies not assessing depression through clinical diagnostic instrument or validated, continuous scale (i.e. by self-reported diagnosis or single-item only) were excluded. Studies of special populations of smokers (e.g. psychiatric, medical) without major depression were excluded. We included qualitative/quantitative reviews and clinical trial, human laboratory-based, observational and epidemiological study designs. Non-peer-reviewed publications and case studies were excluded.

We excluded publications that both reviewers agreed did not meet eligibility criteria. Authors resolved disagreements by consensus.

## RESULTS


### Results of literature searches

Our searches of databases identified 852 unique citations (Fig. 1). We screened 852 records by abstract and 453 full-text papers. Of these, 297 papers were included in the qualitative synthesis. Publications incorporated in the narrative review were those which contributed most directly to our theoretical framework.

## PSYCHOLOGICAL MECHANISMS PROMOTING SMOKING MAINTENANCE AND RELAPSE IN DEPRESSED SMOKERS

### Affective processes

While depression is characterized by a wide range of affective, cognitive, behavioral and somatic features [41], evidence is mounting that the affective disturbances in depression may play a qualitatively unique role in depression–smoking comorbidity over and above most non-affective depressive symptoms [15,42,43]. Indeed, symptom-level analyses have shown that high negative affect (NA; experience of subjective distress) and low positive affect (PA; low engagement with the environment [44,45]) are associated uniquely with nicotine dependence severity [46,47], smoking heaviness [48] and smoking relapse risk [42,49–53]. Moreover, low PA accounts for independent variance in relapse risk, above and beyond high NA [42,49], suggesting that these two processes reflect unique etiological influences on smoking.



**Figure 1** Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram: summary of search and selection

The notion that two distinct affective processes promote smoking is consistent with multi-dimensional models of psychopathology and personality which purport that low PA and high NA are empirically distinct overarching psychological dimensions that have unique psychosocial and biological etiologies [54–56]. The low PA dimension includes constructs related to appetitive emotion, including diminished pleasure, interest, expectancy, motivation and reinforcement learning [54,57], whereas the NA dimension includes constructs related to aversive emotion including sadness, irritability, anxiety, low distress tolerance and neuroticism [54]. In the proposed theoretical model, low PA and high NA represent distinct states that each worsen more rapidly following abstinence for depressed versus non-depressed smokers [58,59] and serve to augment smoking motivation.

First, as nicotine dependence increases, low PA signals the greater reinforcement value of smoking. In the overall population of smokers and non-smokers, nicotine moderately improves PA and reward responsivity [60]. Crucially, smokers with prominent symptoms of anhedonia (i.e. the decreased capacity to experience pleasure) experience frequent bouts of low PA and endorse greater nicotine-induced increases in PA and reward responsivity following smoking [61]. While smoking itself is more reinforcing in the anhedonic state, a greater experience of reward may also be derived from other non-nicotine reinforcers, such as music, and contribute to the greater net value of smoking in the anhedonic state [62]. Following acute

withdrawal, regular smokers show moderate-sized reductions in PA and reward responsivity [51,59,63], while anhedonic smokers exhibit greater reductions in PA, reward responsivity and urge to smoke to enhance PA [64–67]. Potentially, pre-existing deficits in hedonic experience among depressed smokers may be unmasked and exacerbated by nicotine withdrawal, producing strong motivation to resume smoking to end a temporary ‘time out’ in reward experience and obtain smoking’s positive reinforcing effects [57]. Thus, low PA is established as a signal for the increased reinforcement value of smoking, particularly among depressed smokers with prominent symptoms of anhedonia.

Secondly, elevated NA also serves as a motivational state driving smoking maintenance among depressed smokers. Although escape or avoidance of NA is thought to be the pre-potent motive for addictive drug use [68], the relationship between smoking and NA is complex. Nicotine is thought to have antidepressant properties [69–72] and experience of NA is shown, reliably, to decrease latency to smoke and increase number of puffs consumed [73]. However, while smoking reverses withdrawal-induced NA [74–77], there is little evidence that it alleviates experimentally induced NA [77–82].

Depressed smokers probably fail to distinguish NA provoked by withdrawal versus other sources (i.e. environmental stressors), and thus seek out smoking in response to both states. Nicotine withdrawal is characterized by a marked increase in NA among smokers in the

general population [83,84]. Depression-prone smokers experience even greater deprivation-induced increases in NA [85–87], which could reflect an unmasking of a propensity towards negative affective states [57]. Accordingly, depressed smokers [88] and individuals prone to depression [89] are especially likely to smoke for affect regulation motives. NA thus provides a reliable signal for the greater reinforcement value of smoking and becomes established as a motivational state which primes smoking behavior, particularly in depressed smokers.

### Cognitive impairment

In addition to affective disturbances, depression is characterized by non-specific cognitive deficits that span domains of attention, memory, processing speed and all aspects of executive functioning [90–96]. Although the aggregated effect size estimates of cognitive deficits in major depression are small to medium [93,97], these deficits are clinically significant [93,97], functionally impairing [98–100] and may persist even after an acute depressive episode has abated [90]. Crucially, cognitive impairment associated with depression is similar to that observed during nicotine withdrawal, particularly in domains of executive functioning and attention [101–103]. In a general population of smokers, smoking abstinence is associated with impaired sustained attention, working memory and response inhibition [104], and biases cognition towards the perceived salience of smoking-related stimuli ([105,106], but also see [107]). Depressed smokers are shown to experience even greater withdrawal-induced deficits in cognitive performance [108], which may reflect the overlap (or perhaps additive effect) of cognitive deficits in depression with cognitive deficits induced by smoking abstinence. Accordingly, depressed smokers may maintain smoking behavior in order to attenuate cognitive deficits, especially when engaged in effortful or cognitively demanding tasks [109,110]. Importantly, cognitive deficits are associated prospectively with smoking relapse for both smokers in the general population [111,112] and depression-prone smokers [113]. Thus, background cognitive deficits in depression may summate with acute withdrawal-related cognitive deficits to prime smoking [108].

Our theoretical model posits that cognitive impairment comes to signal the additional reinforcement of smoking produced by the resulting improvement in cognitive functioning. However, far fewer studies have examined cognitive versus affective processes underlying smoking maintenance in depressed smokers, limiting the definitive conclusions that can be drawn. Preliminary evidence suggests that depressed smokers endorse smoking in part to manage negative intrusive thoughts and facilitate concentration and problem-solving [114]. Additionally, depressed versus non-depressed smokers showed improved

reaction-time performance after smoking, suggesting that they experienced greater cognitive enhancement compared to baseline [115]. Further studies are needed to test whether depressed versus non-depressed smokers experience greater reinforcement value of smoking in the face of cognitive impairment, as suggested by an incentive learning theory account.

### Proposed incentive learning model of smoking and depression and distinction from negative reinforcement-based models

Negative reinforcement models may be divided into three categories based upon the proposed mechanisms by which adverse states promote drug use. All three categories make the common prediction that depressed smokers experience frequent bouts of high NA, low PA and cognitive impairment, which intensify rapidly during acute abstinence and function to promote smoking maintenance and relapse [80–83]. The distinction between the three categories of negative reinforcement accounts lies in their depiction of the learning processes by which these adverse states acquire control over smoking behavior. The early negative reinforcement accounts referred to the adverse states as internal instrumental discriminative stimuli (or  $S^D$ s for short) because they ‘set the occasion’ or provide the context [116] in which smoking is more reinforcing; but exactly how these internal  $S^D$ s prime smoking behavior was not specified fully [117,118].

The later wave of negative reinforcement theories [119], allostasis theories [120,121] and more recent incentive habit theories [122] have sought to specify how adverse internal states prime smoking behavior. These theories follow Hull’s [123] stimulus–response/reinforcement view of instrumental discrimination learning, according to which adverse internal stimuli (S) form a direct association with smoking response sequences (R) as a result of reinforcement from smoking. The S–R association between adverse states and smoking responses is especially strong because smoking is more reinforcing in the adverse states, which strengthens the S–R association. This learning enables adverse states to elicit smoking behavior directly, without retrieving knowledge of the consequences of the behavior. Accordingly, S–R-based control of smoking has been called automatic, unconscious, pre-conscious, habitual and compulsive. Such S–R accounts are attractive because they can explain how adverse internal states could promote smoking behavior bypassing the individual’s intentions to remain abstinent, which could account for depressed smokers’ elevated rates of smoking cessation failure, despite high motivation to quit. These accounts ascribe to internal stimuli the same form of direct control over response selection that ‘standard’ habit theories of addiction have ascribed to external drug-related cues [124–126].

However, S–R accounts of action control by internal states have been challenged on logical grounds by researchers from the behavior-analyst tradition [127–130]. The grounds for this challenge are that the behavioral sequences needed to yield nicotine reinforcement differ vastly depending on the context (e.g. purchasing cigarettes from a store versus from a machine; smoking during a break versus in a bar). Internal states on their own are not sufficiently discriminating to elicit the response sequence that is required to produce nicotine reinforcement in these various external contexts via simple S–R/reinforcement learning [127–130]. Instead, from the behavior-analyst perspective, adverse internal states function as motivating operations (or MOs) because they predict that smoking has greater reinforcement value independently of the external context and the response currently required to produce that reinforcer. MOs are thought to motivate behavior by interacting with the external  $S^D$ s. Specifically, by virtue of signaling that a smoking reinforcement has a greater value, MOs lower the threshold of activation required for external  $S^D$ s to elicit the specific response sequences required to produce smoking reinforcement in the external context. On this account, adverse states do not elicit smoking directly (as predicted by S–R theories) but, rather, modulate the ability of external discriminative stimuli to evoke smoking behavior through S–R learning. The main weakness of this account is that it does not explain fully the nature of the interaction which allows adverse states (MOs) to modulate control by external stimuli over response selection.

Incentive learning theory addresses this limitation by suggesting that adverse states promote smoking behavior through a conjunction of explicit desire and goal-directed instrumental knowledge [32–34]; see also [35]. On this view, adverse states function as motivational states (like MOs) which, by virtue of predicting the greater reinforcement value of smoking, come to elicit an expectation of the greater reinforcement value of smoking (i.e. greater subjective desire to smoke). Smokers also acquire explicit goal-directed instrumental knowledge of the specific response sequences that yield nicotine reinforcement in different external contexts. These two forms of knowledge are then synthesized in a cognitive inference. The experience of an adverse state generates an expectation of the greater reinforcement value of smoking which is combined with goal-directed instrumental knowledge of the response sequence required to produce the desired smoking outcome given the specific external context [36–39]. The incentive learning account is unique among the categories of negative reinforcement theory in predicting that adverse internal states prime smoking behavior via a conjunction of subjective desire to smoke and instrumental knowledge of the responses required to produce that outcome in the current context.


### Proposed theory

As shown in Fig. 2, we propose a novel application of the incentive learning account to co-occurring smoking and depression. Figure 2a illustrates the acute smoking phase in which depressed smokers develop an expectation of greater reinforcement value of smoking in three specific motivational states: NA, low PA and cognitive impairment. As smoking persists, Fig. 2b displays the role of chronic smoking in worsening NA, low PA and cognitive impairment over time due to frequent bouts of nicotine withdrawal. Belief about the high reward value of smoking in these motivational states, particularly during abstinence, is conceptualized as the primary trigger for smoking maintenance and relapse following a quit attempt in depressed smokers.

Although this theoretical framework is relevant to smokers in the general population, we believe that the motivational states are especially effective in depressed smokers. First, those with depression experience more intense adverse states and greater reinforcement value of smoking in these states, so these states become more powerful motivators of smoking. Secondly, depression is associated with a more severe withdrawal syndrome, adding further intensity to the adverse states as motivators of smoking behavior. Lastly, depression is thought to counter acute satiety, so depressed smokers sustain a greater expected value of smoking even immediately after smoking.

The unique prediction of the incentive learning account (compared to the S–R account) is that subjective desire to smoke prompted by adverse states and goal-directed instrumental knowledge of the effective smoking response in each context are integrated to drive smoking behavior. One source of support for this claim is the finding that experimental induction of stress or NA provoke increases in both smoking desire and smoking behavior [79,82,131–139]. Although the mood-induced increase in smoking desire may cause the smoking behavior, as anticipated by incentive learning theory, S–R-based negative reinforcement accounts would argue that the increase in smoking desire is actually epiphenomenal in relation to smoking behavior. The causal status of subjective desire in controlling behavior remains an unresolved scientific question [34,140].

We recently reported direct empirical evidence supporting the incentive learning account over the S–R account of how negative mood provokes smoking [40]. A unique prediction of the incentive learning account is that induced negative mood should be able to augment a novel tobacco-seeking response in an extinction test through integration of (1) expected high value of tobacco and (2) knowledge of the instrumental response required to produce that outcome in the context. By contrast, the S–R account predicts that an induced negative mood should not be able to augment a novel tobacco-seeking



**Figure 2** (a) Acute effect of smoking in depressed smokers. (b) Chronic effect of smoking in depressed smokers. (a) Incentive learning processes by which specific states (i.e. negative affect, low positive affect, and cognitive impairment) are alleviated acutely by smoking, and thus signal the enhanced incentive value of smoking. (b) Enhanced incentive reward value fosters persistence of smoking through goal-directed selection of this behavioral choice. Chronically, smoking engages allostatic processes such that the aversive states are augmented. These aversive states in turn signal the higher incentive value of acute smoking, thus completing the vicious cycle

response in an extinction test. This is because the S–R account requires direct experience of the greater value of tobacco in the induced mood state to strengthen the association between that state and the novel tobacco-seeking response. Such S–R learning is not possible because the tobacco reinforcer is omitted from the extinction test. The results of our study [40] showed that inducing a negative mood state in smokers augmented tobacco-seeking in an extinction test, confirming that NA primes tobacco-seeking through an inference of knowledge about the greater value of tobacco in the mood state and knowledge of which response produces tobacco in the current context.

We generalize this finding to suggest that when depressed individuals experience an adverse state (NA, low PA or cognitive impairment), which is heightened during abstinence, this state provokes an expectation of the current high value of smoking, which is integrated with knowledge of the response sequence required to smoke in

the context, to drive selection of that behavior over alternatives [38]. Below, we review implications of our proposed theory for pharmacological and behavioral interventions for smoking cessation in depressed smokers.

## DISCUSSION

### Treatment implications of the incentive learning-based theoretical model: guiding principles

The foremost prediction made by the incentive learning account is that adverse internal states are the primary drivers of smoking behavior in depressed individuals. Accordingly, experimental treatment approaches which seek to modify reactivity to external smoking cues (e.g. via cognitive bias modification [141]) are unlikely to be effective in depressed smokers. Rather, treatments should identify the adverse motivational states that are the primary drivers of smoking in each individual and personalize treatment to target

those states. Further, effective intervention strategies should address smokers' beliefs about the high reward value of smoking in these motivational states. In sum, our theory suggests that treatments which (1) attenuate adverse internal states and (2) reverse positive expectancies associated with smoking are most likely to achieve cessation among depressed smokers.

### Targeted pharmacological interventions

Consistent with our theory, pharmacological interventions may be particularly effective in depressed smokers by ameliorating the motivational states which raise the expected value of smoking: high NA, low PA and cognitive impairment. In particular, varenicline has cognitive-enhancing effects in both treatment-motivated smokers [142] and non-smokers [143], and reduces the cognitive impairment that accompanies withdrawal [144]. Bupropion is also shown to be an effective pharmacological intervention among depressed smokers [145,146], possibly through its effects on affective functioning [88,147]. Further, given that multiple withdrawal-related motivational states may interact or summate to motivate smoking among depressed smokers, combination pharmacotherapy (i.e. combined varenicline and bupropion or combination nicotine replacement therapy [148–150]) may be particularly warranted for this population to address each state optimally. As studies of pharmacological agents have focused largely upon cessation outcomes rather than mediating variables, future research testing the effects of medications on the motivational states identified in this review could help to guide pharmacological treatment for depressed smokers.

### Targeted behavioral interventions

To date, NA has been the primary component of depression targeted characteristically by behavioral interventions in smokers with comorbid depression [151–154]. Expanding behavioral interventions to also target low PA explicitly could improve smoking outcomes for smokers with depression. Behavioral activation—an efficacious treatment for major depressive disorder that increases engagement in reinforcing activities congruent with a person's goals [155]—may counteract withdrawal-related anhedonia and increase quit rates by increasing exposure to alternative sources of non-smoking reinforcement [156].

Our model states further that relations between motivational states and goal-directed smoking behavior are mediated by expectancies that smoking will improve these states. Behavioral interventions which address these expectancies (i.e. by challenging maladaptive beliefs about the long-term mood regulating effects of nicotine) could help to break the link between cognitive/affective deficits and smoking maintenance among depressed smokers.

Although smokers with depression believe commonly that smoking helps to regulate their negative mood states [157,158], evidence suggests that smoking actually leads to worsening of mental health symptoms over time and, conversely, quitting leads to improved mental health status [159]. Thus, behavioral interventions should emphasize the distinction between withdrawal reversal and true mood improvement to allow smokers to learn that the benefits of smoking are short- but not long-term, and restricted to the withdrawal syndrome and not environmental stressors. Novel strategies incorporating self-monitoring and personalized feedback could help to improve the salience and credibility of this message, particularly among depressed smokers.

### Conclusions

Our proposed theory posits that smoking is maintained among depressed smokers through the expectation that smoking will alleviate specific states, in integration with the goal-directed choice of smoking over alternate behaviors. Drawing from a systematic review of the smoking-depression literature, we propose high NA, low PA and cognitive impairment as the three motivational states that drive this process. While we have chosen a narrative review format in order to frame our conceptual model, this approach limited our ability to systematically assess for risk of bias and strength of evidence across studies. As the treatment literature on smoking and depression expands, it will be increasingly important for future reviews of this topic to include both qualitative and quantitative methods of analysis.

Our review identifies several directions for future research. First, it remains unclear how awareness of cognitive deficits interacts with awareness of affective states (i.e. low PA and high NA) to provide the motivational signal promoting goal-directed smoking behavior. Studies that characterize each of these withdrawal-related states among depressed smokers, as well as their unique and shared contribution to tobacco-seeking behavior, are needed. Secondly, although our theory holds that expectancies play a causal role in smoking maintenance, it has not been specified fully how knowledge of reward values and context-dependent response requirements translate into actual action selection. Thirdly, cognitive processes among depressed smokers have received relatively little research attention, but we believe cognitive impairment represents a key motivational state maintaining smoking behavior in this population [160]. Future research should elucidate further the extent to which depressed smokers smoke for cognitive enhancement motives, benefit differentially from smoking in terms of functional cognitive outcomes and respond to pro-cognitive agents as part of a smoking cessation intervention. Lastly, as depression and

smoking co-occur commonly with other mental health concerns (i.e. substance use disorders, anxiety disorders) [161–163], identifying the unique versus shared incentive states underlying each of these conditions in order to guide integrated treatment is an important priority.

#### Declaration of interests

Dr. Histman has served on a scientific advisory board for Pfizer and receives study medication and placebo free of charge from Pfizer for use in ongoing National Institutes of Health funded clinical trials.

#### Acknowledgments

This work is supported by the National Cancer Institute and National Institute on Drug Abuse of the United States National Institutes of Health (Grant Numbers F32DA036947 and R01CA184211). J.W.C. is supported by Merit Review Award 101CX00056 from the US Department of Veterans Affairs. We thank Dr Robert West for feedback on an earlier draft of this manuscript.

#### References

- Grant B. E., Hasin D. S., Chou S. P., Stinson F. S., Dawson D. A. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. *Arch Gen Psychiatry* 2004; **61**: 1107–15.
- Hall S. M., Prochaska J. J. Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings. *Annu Rev Clin Psychol* 2009; **5**: 409–31.
- Lasser K., Boyd J. W., Woolhandler S., Himmelstein D. U., McCormick D., Bor D. H. Smoking and mental illness: a population-based prevalence study. *JAMA* 2000; **284**: 2606–10.
- Lawrence D., Mitrou F., Zubrick S. R. Smoking and mental illness: results from population surveys in Australia and the United States. *BMC Public Health* 2009; **9**: 285.
- Ziedonis D., Hitsman B., Beckham J. C., Zvolensky M., Adler L. E., Audrain-McGovern J. *et al.* Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. *Nicotine Tob Res* 2008; **10**: 1691–715.
- Cook B. L., Wayne G. E., Kafali E. N., Liu Z., Shu C., Flores M. Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. *JAMA* 2014; **311**: 172–82.
- Breslau N., Kilbey M. M., Andreski P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiologic study of young adults. *Am J Psychiatry* 1992; **149**: 464–9.
- Weinberger A. H., Desai R. A., McKee S. A. Nicotine withdrawal in U.S. smokers with current mood, anxiety, alcohol use, and substance use disorders. *Drug Alcohol Depend* 2010; **108**: 7–12.
- Goodwin R. D., Zvolensky M. J., Keyes K. M., Hasin D. S. Mental disorders and cigarette use among adults in the United States. *Am J Addict* 2012; **21**: 416–23.
- Grant B. E., Hasin D. S., Chou S., Stinson F. S., Dawson D. A. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. *Arch Gen Psychiatry* 2004; **61**: 1107–15.
- Khaled S. M., Bulloch A., Exner D. V., Patten S. B. Cigarette smoking, stages of change, and major depression in the Canadian population. *Can J Psychiatry* 2009; **54**: 204–8.
- Khaled S. M., Bulloch A. G., Williams J. V., Lavorato D. H., Patten S. B. Major depression is a risk factor for shorter time to first cigarette irrespective of the number of cigarettes smoked per day: evidence from a national population health survey. *Nicotine Tob Res* 2011; **13**: 1059–67.
- Acton G. S., Kunz J. D., Wilson M., Hall S. M. The construct of internalization: conceptualization, measurement, and prediction of smoking treatment outcome. *Psychol Med* 2005; **35**: 395–408.
- Prochaska J. J., Rossi J. S., Redding C. A., Rosen A. B., Tsoh J. Y., Humfleet G. L. *et al.* Depressed smokers and stage of change: implications for treatment interventions. *Drug Alcohol Depend* 2004; **76**: 143–51.
- Buckner J. D., Farris S. G., Zvolensky M. J., Shah S. M., Leventhal A. M., Minnix J. A. *et al.* Dysphoria and smoking among treatment seeking smokers: the role of smoking-related inflexibility/avoidance. *Am J Drug Alcohol Abuse* 2015; **41**: 45–51.
- Cooper J., Borland R., McKee S. A., Yong H. H., Dugué P. A. Depression motivates quit attempts but predicts relapse: differential findings for gender from the International Tobacco Control study. *Addiction* 2016; **111**: 1438–47.
- Williams J. M., Stroup T. S., Brunette M. F., Raney L. E. Integrated care: tobacco use and mental illness: a wake-up call for psychiatrists. *Psychiatr Serv* 2014; DOI: 10.1176/appi.ps.201400235.
- Druss B. G., Zhao L., Von Esenwein S., Morrato E. H., Marcus S. C. Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative US survey. *Med Care* 2011; **49**: 599–604.
- Colton C., Manderscheid R. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. *Prev Chronic Dis* 2006; **3**: A42.
- Tiihonen J., Lönnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A. *et al.* 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (fin11 study). *Lancet* 2009; **374**: 620–7.
- Kahler C. W., Spillane N. S., Busch A. M., Leventhal A. M. Time-varying smoking abstinence predicts lower depressive symptoms following smoking cessation treatment. *Nicotine Tob Res* 2011; **13**: 146–50.
- Mathew A. R., Robinson J. D., Norton P. J., Cinciripini P. M., Brown R. A., Blalock J. A. Affective trajectories before and after a quit attempt among smokers with current depressive disorders. *Nicotine Tob Res* 2013; **15**: 1807–15.
- Taylor G., McNeill A., Girling A., Farley A., Lindson-Hawley N., Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. *BMJ* 2014; **348**: g1151.
- Berlin I., Chen H., Covey L. S. Depressive mood, suicide ideation and anxiety in smokers who do and smokers who do not manage to stop smoking after a target quit day. *Addiction* 2010; **105**: 2209–16.

25. McDermott M. S., Marteau T. M., Hollands G. J., Hankins M., Aveyard P. Change in anxiety following successful and unsuccessful attempts at smoking cessation: cohort study. *Br J Psychiatry* 2013; **202**: 62–7.
26. Bakhshaie J., Zvolensky M. J., Goodwin R. D. Cigarette smoking and the onset and persistence of depression among adults in the United States: 1994–2005. *Compr Psychiatry* 2014; DOI: 10.1016/j.comppsy.2014.10.012.
27. US Department of Health and Human Services (USDHHS). *The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General*. Atlanta, GA: USDHHS, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
28. Bowins B. Depression: discrete or continuous? *Psychopathology* 2015; **48**: 69–78.
29. Angst J., Sellar R., Merikangas K. R. Depressive spectrum diagnoses. *Compr Psychiatry* 2000; **41**: 39–47.
30. Ayuso-Mateos J. L., Nuevo R., Verdes E., Naidoo N., Chatterji S. From depressive symptoms to depressive disorders: the relevance of thresholds. *Br J Psychiatry* 2010; **196**: 365–71.
31. Anthenelli R. M., Morris C., Ramey T. S., Dubrava S. J., Tsilkos K., Russ C. *et al.* Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. *Ann Intern Med* 2013; **159**: 390–400.
32. Dickinson A., Balleine B. W. The cognitive/motivational interface. In: Kringelbach M. L., Berridge K. C., editors. *Pleasures of the Brain. The Neural Basis of Taste, Smell and Other Rewards*. Oxford, UK: Oxford University Press; 2010, pp. 74–84.
33. Balleine B. W., Ball J., Dickinson A. Benzodiazepine-induced outcome revaluation and the motivational control of instrumental action in rats. *Behav Neurosci* 1994; **108**: 573–89.
34. Heyes C., Dickinson A. The intentionality of animal action. *Mind Lang* 1990; **5**: 87–103.
35. Pittenger S. T., Bevins R. A. Interoceptive conditioning with a nicotine stimulus is susceptible to reinforcer devaluation. *Behav Neurosci* 2013; **127**: 465–73.
36. Bradfield L. A., Balleine B. W. Hierarchical and binary associations compete for behavioral control during instrumental biconditional discrimination. *J Exp Psychol Anim Behav Process* 2013; **39**: 2–13.
37. Trask S., Bouton M. Contextual control of operant behavior: Evidence for hierarchical associations in instrumental learning. *Learn Behav* 2014; **42**: 281–8.
38. Hogarth L., Troisi J. R. 2nd. A hierarchical instrumental decision theory of nicotine dependence. In: Balfour D. J. K., Munafò M. R., editors. *The Neurobiology and Genetics of Nicotine and Tobacco. Current Topics in Behavioral Neurosciences*. Gewerbestrasse, Switzerland: Springer International Publishing; 2015, pp. 165–91.
39. Hogarth L., Retzler C., Munafò M. R., Tran D. M. D., Troisi J. R. 2nd, Rose A. K. *et al.* Extinction of cue-evoked drug-seeking relies on degrading hierarchical instrumental expectancies. *Behav Res Ther* 2014; **59**: 61–70.
40. Hogarth L., He Z., Chase H. W., Wills A. J., Troisi J. R. 2nd, Leventhal A. M. *et al.* Negative mood reverses devaluation of goal-directed drug-seeking favouring an incentive learning account of drug dependence. *Psychopharmacology (Berl)* 2015; **232**: 3235–47.
41. American Psychiatric Association (APA). *Diagnostic and Statistical Manual of Mental Disorders (DSM-5®)*. Arlington, VA: American Psychiatric Publishers; 2013.
42. Leventhal A. M., Ramsey S. E., Brown R. A., LaChance H. R., Kahler C. W. Dimensions of depressive symptoms and smoking cessation. *Nicotine Tob Res* 2008; **10**: 507–17.
43. Haas A. L., Munoz R. F., Humfleet G. L., Reus V. I., Hall S. M. Influences of mood, depression history, and treatment modality on outcomes in smoking cessation. *J Consult Clin Psychol* 2004; **72**: 563–70.
44. Watson D., Clark L. A., Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. *J Pers Soc Psychol* 1988; **54**: 1063.
45. Watson D., Weber K., Assenheimer J. S., Clark L. A., Strauss M. E., McCormick R. A. Testing a tripartite model: I. Evaluating the convergent and discriminant validity of anxiety and depression symptom scales. *J Abnorm Psychol* 1995; **104**: 3–14.
46. Leventhal A. M., Kahler C. W., Ray L. A., Zimmerman M. Refining the depression–nicotine dependence link: patterns of depressive symptoms in psychiatric outpatients with current, past, and no history of nicotine dependence. *Addict Behav* 2009; **34**: 297–303.
47. Mickens L., Greenberg J., Ameringer K. J., Brightman M., Sun P., Leventhal A. M. Associations between depressive symptom dimensions and smoking dependence motives. *Eval Health Prof* 2011; **34**: 81–102.
48. Leventhal A. M., Zvolensky M. J., Schmidt N. B. Smoking-related correlates of depressive symptom dimensions in treatment-seeking smokers. *Nicotine Tob Res* 2011; **13**: 668–76.
49. Leventhal A. M., Piper M. E., Japuntich S. J., Baker T. B., Cook J. W. Anhedonia, depressed mood, and smoking cessation outcome. *J Consult Clin Psychol* 2014; **82**: 122–9.
50. Cook J., Spring B., McChargue D., Doran N. Effects of anhedonia on days to relapse among smokers with a history of depression: a brief report. *Nicotine Tob Res* 2010; **12**: 978–82.
51. Cook J. W., Piper M. E., Leventhal A. M., Schlam T. R., Fiore M. C., Baker T. B. Anhedonia as a component of the tobacco withdrawal syndrome. *J Abnorm Psychol* 2015; **124**: 215–25.
52. Hitsman B., Pingitore R., Spring B., Mahabeshwarkar A., Mizes J. S., Segraves K. A. *et al.* Antidepressant pharmacotherapy helps some cigarette smokers more than others. *J Consult Clin Psychol* 1999; **67**: 547–54.
53. Schnoll R. A., Leone F. T., Hitsman B. Symptoms of depression and smoking behaviors following treatment with transdermal nicotine patch. *J Addict Dis* 2013; **32**: 46–52.
54. Clark L. A., Watson D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. *J Abnorm Psychol* 1991; **100**: 316–36.
55. Elliot A. J., Thrash T. M. Approach–avoidance motivation in personality: approach and avoidance temperaments and goals. *J Pers Soc Psychol* 2002; **82**: 804–18.
56. Lane R. D., Reiman E. M., Bradley M. M., Lang P. J., Ahern G. L., Davidson R. J. *et al.* Neuroanatomical correlates of pleasant and unpleasant emotion. *Neuropsychologia* 1997; **35**: 1437–44.
57. Leventhal A. M., Zvolensky M. J. Anxiety, depression, and cigarette smoking: a transdiagnostic vulnerability framework to understanding emotion–smoking comorbidity. *Psychol Bull* 2015; **141**: 176–212.
58. Audrain-McGovern J., Wileyto E. P., Ashare R., Cuevas J., Strasser A. A. Reward and affective regulation in depression-prone smokers. *Biol Psychiatry* 2014; **76**: 689–97.

59. Pergadia M. L., Der-Avakian A., D'Souza M. S., Madden P. A., Heath A. C., Shiffman S. *et al.* Association between nicotine withdrawal and reward responsiveness in humans and rats. *JAMA Psychiatry* 2014; **71**: 1238–45.
60. Dawkins L., Powell J. H., West R., Powell J., Pickering A. A double-blind placebo controlled experimental study of nicotine: I—effects on incentive motivation. *Psychopharmacology (Berl)* 2006; **189**: 355–67.
61. Cook J. W., Spring B., McChargue D. Influence of nicotine on positive affect in anhedonic smokers. *Psychopharmacology (Berl)* 2007; **192**: 87–95.
62. Perkins K. A., Karelitz J. L. Reinforcement enhancing effects of nicotine via smoking. *Psychopharmacology (Berl)* 2013; **228**: 479–86.
63. Leventhal A. M., Waters A. J., Moolchan E. T., Heishman S. J., Pickworth W. B. A quantitative analysis of subjective, cognitive, and physiological manifestations of the acute tobacco abstinence syndrome. *Addict Behav* 2010; **35**: 1120–30.
64. Leventhal A. M., Munafo M., Tidey J. W., Sussman S., Monterosso J. R., Sun P. *et al.* Anhedonia predicts altered processing of happy faces in abstinent cigarette smokers. *Psychopharmacology (Berl)* 2012; **222**: 343–51.
65. Leventhal A., Trujillo M., Ameringer K., Tidey J., Sussman S., Kahler C. Anhedonia and the relative reward value of drug and nondrug reinforcers in cigarette smokers. *J Abnorm Psychol* 2014; **123**: 375–86.
66. Leventhal A. M., Waters A. J., Kahler C. W., Ray L. A., Sussman S. Relations between anhedonia and smoking motivation. *Nicotine Tob Res* 2009; **11**: 1047–54.
67. Cook J. W., Spring B., McChargue D., Hedeker D. Hedonic capacity, cigarette craving, and diminished positive mood. *Nicotine Tob Res* 2004; **6**: 39–47.
68. Baker T. B., Piper M. E., McCarthy D. E., Majeskie M. R., Fiore M. C. Addiction motivation reformulated: an affective processing model of negative reinforcement. *Psychol Rev* 2004; **111**: 33–51.
69. Balfour D. J., Ridley D. L. The effects of nicotine on neural pathways implicated in depression: a factor in nicotine addiction? *Pharmacol Biochem Behav* 2000; **66**: 79–85.
70. Tizabi Y., Overstreet D. H., Rezvani A. H., Louis V. A., Clark E. Jr., Janowsky D. S. *et al.* Antidepressant effects of nicotine in an animal model of depression. *Psychopharmacology (Berl)* 1999; **142**: 193–9.
71. Vázquez-Palacios G., Bonilla-Jaime H., Velázquez-Moctezuma J. Antidepressant effects of nicotine and fluoxetine in an animal model of depression induced by neonatal treatment with clomipramine. *Prog Neuropsychopharmacol Biol Psychiatry* 2005; **29**: 39–46.
72. Mineur Y. S., Picciotto M. R. Biological basis for the co-morbidity between smoking and mood disorders. *J Dual Diagn* 2009; **5**: 122–30.
73. Heckman B. W., Carpenter M. J., Correa J. B., Wray J. M., Saladin M. E., Froeliger B. *et al.* Effects of experimental negative affect manipulations on *ad libitum* smoking: a meta-analysis. *Addiction* 2015; **110**: 751–60.
74. Hatsukami D. K., Hughes J. R., Pickens R. W., Svikis D. Tobacco withdrawal symptoms: an experimental analysis. *Psychopharmacology (Berl)* 1984; **84**: 231–6.
75. Hughes J. R., Hatsukami D. K., Pickens R. W., Krahn D., Malin S., Luknic A. Effect of nicotine on the tobacco withdrawal syndrome. *Psychopharmacology (Berl)* 1984; **83**: 82–7.
76. Parrott A. C. Stress modulation over the day in cigarette smokers. *Addiction* 1995; **90**: 233–44.
77. Perkins K. A., Karelitz J. L., Conklin C. A., Sayette M. A., Giedgowd G. E. Acute negative affect relief from smoking depends on the affect situation and measure but not on nicotine. *Biol Psychiatry* 2010; **67**: 707–14.
78. Perkins K. A., Ciccocioppo M., Conklin C. A., Milanak M. E., Grotenthaler A., Sayette M. A. Mood influences on acute smoking responses are independent of nicotine intake and dose expectancy. *J Abnorm Psychol* 2008; **117**: 79.
79. Conklin C. A., Perkins K. A. Subjective and reinforcing effects of smoking during negative mood induction. *J Abnorm Psychol* 2005; **114**: 153–64.
80. Kassel J. D., Shiffman S. Attentional mediation of cigarette smoking's effect on anxiety. *Health Psychol* 1997; **16**: 359–68.
81. Kassel J. D., Unrod M. Smoking, anxiety, and attention: support for the role of nicotine in attentionally mediated anxiety. *J Abnorm Psychol* 2000; **109**: 161–6.
82. Willner P., Jones C. Effects of mood manipulation on subjective and behavioural measures of cigarette craving. *Behav Pharmacol* 1996; **7**: 355–63.
83. Hughes J. R. Effects of abstinence from tobacco: Etiology, animal models, epidemiology, and significance: a subjective review. *Nicotine Tob Res* 2007; **9**: 329–39.
84. Piper M. E. Withdrawal: Expanding a key addiction construct. *Nicotine Tob Res* 2015; **17**: 1405–15.
85. Leventhal A. M., Ameringer K. J., Osborn E., Zvolensky M. J., Langdon K. J. Anxiety and depressive symptoms and affective patterns of tobacco withdrawal. *Drug Alcohol Depend* 2013; **133**: 324–9.
86. Gilbert D. G., McClernon F. J., Rabinovich N. E., Dibb W. D., Plath L. C., Hiyane S. *et al.* EEG, physiology, and task-related mood fail to resolve across 31 days of smoking abstinence: relations to depressive traits, nicotine exposure, and dependence. *Exp Clin Psychopharmacol* 1999; **7**: 427–43.
87. Audrain-McGovern J., Wileyto E. P., Ashare R., Cuevas J., Strasser A. A. Reward and affective regulation in depression-prone smokers. *Biol Psychiatry* 2014; **76**: 689–97.
88. Lerman C., Audrain J., Orleans C. T., Boyd R., Gold K., Main D. *et al.* Investigation of mechanisms linking depressed mood to nicotine dependence. *Addict Behav* 1996; **21**: 9–19.
89. Brody C. L., Hamer D. H., Haaga D. A. Depression vulnerability, cigarette smoking, and the serotonin transporter gene. *Addict Behav* 2005; **30**: 557–66.
90. Bora E., Harrison B., Yücel M., Pantelis C. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. *Psychol Med* 2013; **43**: 2017–26.
91. Trivedi M. H., Greer T. L. Cognitive dysfunction in unipolar depression: implications for treatment. *J Affect Disord* 2014; **152–154**: 19–27.
92. Hammar A., Ardal G. Cognitive functioning in major depression—a summary. *Front Hum Neurosci* 2009; **3**: 26.
93. Lee R. S., Hermens D. E., Porter M. A., Redoblado-Hodge M. A. A meta-analysis of cognitive deficits in first-episode major depressive disorder. *J Affect Disord* 2012; **140**: 113–24.
94. Murrrough J. W., Iacoviello B., Neumeister A., Charney D. S., Iosifescu D. V. Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. *Neurobiol Learn Mem* 2011; **96**: 553–63.

95. Austin M.-P., Mitchell P., Goodwin G. M. Cognitive deficits in depression possible implications for functional neuropathology. *Br J Psychiatry* 2001; **178**: 200–6.
96. Millan M. J., Agid Y., Brüne M., Bullmore E. T., Carter C. S., Clayton N. S. *et al.* Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. *Nat Rev Drug Discov* 2012; **11**: 141–68.
97. McIntyre R. S., Cha D. S., Soczynska J. K., Woldeyohannes H. O., Gallagher L. A., Kudlow P. *et al.* Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. *Depress Anxiety* 2013; **30**: 515–27.
98. Evans V. C., Chan S. S., Iverson G. L., Bond D. J., Yatham L. N., Lam R. W. Systematic review of neurocognition and occupational functioning in major depressive disorder. *Neuropsychiatry* 2013; **3**: 97–105.
99. Buist-Bouwman M., Ormel J., de Graaf R., de Jonge P., van Sonderen E., Alonso J. *et al.* Mediators of the association between depression and role functioning. *Acta Psychiatr Scand* 2008; **118**: 451–8.
100. Jaeger J., Berns S., Uzelac S., Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. *Psychiatry Res* 2006; **145**: 39–48.
101. Jacobsen L. K., Krystal J. H., Mencil W. E., Westerveld M., Frost S. J., Pugh K. R. Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. *Biol Psychiatry* 2005; **57**: 56–66.
102. Jacobsen L. K., Mencil W. E., Constable R. T., Westerveld M., Pugh K. R. Impact of smoking abstinence on working memory neurocircuitry in adolescent daily tobacco smokers. *Psychopharmacology (Berl)* 2007; **193**: 557–66.
103. Mendrek A., Monterosso J., Simon S. L., Jarvik M., Brody A., Olmstead R. *et al.* Working memory in cigarette smokers: comparison to non-smokers and effects of abstinence. *Addict Behav* 2006; **31**: 833–44.
104. McClernon F. J., Addicott M. A., Sweitzer M. M. Smoking abstinence and neurocognition: implications for cessation and relapse. *Curr Top Behav Neurosci* 2015; **23**: 193–227.
105. Freeman T. P., Morgan C. J., Beesley T., Curran H. V. Drug cue induced overshadowing: selective disruption of natural reward processing by cigarette cues amongst abstinent but not satiated smokers. *Psychol Med* 2012; **42**: 161–71.
106. Waters A. J., Carter B. L., Robinson J. D., Wetter D. W., Lam C. Y., Kerst W. *et al.* Attentional bias is associated with incentive-related physiological and subjective measures. *Exp Clin Psychopharmacol* 2009; **17**: 247–57.
107. Canamar C. P., London E. Acute cigarette smoking reduces latencies on a smoking Stroop test. *Addict Behav* 2012; **37**: 627–31.
108. Ashare R., Strasser A. A., Wileyto E. P., Cuevas J., Audrain-McGovern J. Cognitive deficits specific to depression-prone smokers during abstinence. *Exp Clin Psychopharmacol* 2014; **22**: 323–31.
109. Hartlage S., Alloy L. B., Vázquez C., Dykman B. Automatic and effortful processing in depression. *Psychol Bull* 1993; **113**: 247–78.
110. Gotlib I. H., Joormann J. Cognition and depression: current status and future directions. *Annu Rev Clin Psychol* 2010; **6**: 285–312.
111. Patterson E., Jepson C., Loughhead J., Perkins K., Strasser A. A., Siegel S. *et al.* Working memory deficits predict short-term smoking resumption following brief abstinence. *Drug Alcohol Depend* 2010; **106**: 61–4.
112. Powell J., Dawkins L., West R., Powell J., Pickering A. Relapse to smoking during unaided cessation: clinical, cognitive and motivational predictors. *Psychopharmacology (Berl)* 2010; **212**: 537–49.
113. Kassel J. D., Yates M., Brown R. A. Baseline reaction time predicts 12-month smoking cessation outcome in formerly depressed smokers. *Psychol Addict Behav* 2007; **21**: 415–9.
114. Malpass D., Higgs S. How is cigarette smoking maintained in depression? Experiences of cigarette smoking in people diagnosed with depression. *Addict Res Theory* 2009; **17**: 64–79.
115. Malpass D., Higgs S. Acute psychomotor, subjective and physiological responses to smoking in depressed outpatient smokers and matched controls. *Psychopharmacology (Berl)* 2007; **190**: 363–72.
116. Skinner B. F. *The Behavior of Organisms: An Experimental Analysis*. Oxford, UK: Appleton-Century; 1938.
117. Pomerleau O. F., Pomerleau C. S. Neuroregulators and the reinforcement of smoking: towards a biobehavioral explanation. *Neurosci Biobehav Rev* 1984; **8**: 503–13.
118. Carmody T. P. Affect regulation, tobacco addiction, and smoking cessation. *J Psychoact Drugs* 1989; **21**: 331–42.
119. Baker T. B., Piper M. E., McCarthy D. E., Majeskie M. R., Fiore M. C. Addiction motivation reformulated: an affective processing model of negative reinforcement. *Psychol Rev* 2004; **111**: 33–51.
120. Koob G. F. Neurobiological substrates for the dark side of compulsivity in addiction. *Neuropharmacology* 2009; **56**: 18–31.
121. Koob G. F., Volkow N. D. Neurocircuitry of addiction. *Neuropsychopharmacology* 2010; **35**: 217–38.
122. Belin D., Belin-Rauscent A., Murray J. E., Everitt B. J. Addiction: failure of control over maladaptive incentive habits. *Curr Opin Neurobiol* 2013; **23**: 564–72.
123. Hull C. L. *Principles of Behavior*. New York: Appleton-Century-Crofts; 1943.
124. Miles F. J., Everitt B. J., Dickinson A. Oral cocaine seeking by rats: action or habit? *Behav Neurosci* 2003; **117**: 927–38.
125. Dickinson A., Wood N., Smith J. W. Alcohol seeking by rats: action or habit? *Q J Exp Psychol B* 2002; **55**: 331–48.
126. Corbit L. H., Nie H., Janak P. H. Habitual alcohol seeking: time course and the contribution of subregions of the dorsal striatum. *Biol Psychiatry* 2012; **72**: 389–95.
127. Dougher M. J., Hackbert L. Establishing operations, cognition, and emotion. *Behav Anal* 2000; **23**: 11–24.
128. Michael J. Establishing operations. *Behav Anal* 1993; **16**: 191–206.
129. Laraway S., Snyckerski S., Olson R., Becker B., Poling A. The motivating operations concept: current status and critical response. *Psychol Rec* 2014; **64**: 601–23.
130. Troisi J. R. 2nd. Sensation within the skin. *ACS Chem Neurosci* 2015; **6**: 209–10.
131. Spring B., Pingitore R., McChargue D. E. Reward value of cigarette smoking for comparably heavy smoking schizophrenic, depressed, and nonpatient smokers. *Am J Psychiatry* 2003; **160**: 316–22.
132. Audrain-McGovern J., Wileyto E. P., Ashare R., Cuevas J., Strasser A. A. Reward and affective regulation in depression-prone smokers. *Biol Psychiatry* 2014; **76**: 689–97.
133. Leventhal A. M., Trujillo M., Ameringer K. J., Tidey J. W., Sussman S., Kahler C. W. Anhedonia and the relative reward value of drug and nondrug reinforcers in cigarette smokers. *J Abnorm Psychol* 2014; **123**: 375–86.

134. Brandon T. H., Wetter D. W., Baker T. B. Affect, expectancies, urges and smoking: do they conform to models of drug motivation and relapse? *Exp Clin Psychopharmacol* 1996; **4**: 29–36.
135. Perkins K. A., Karelitz J. L., Giedgowd G. E., Conklin C. A. Negative mood effects on craving to smoke in women versus men. *Addict Behav* 2013; **38**: 1527–31.
136. Vinci C., Copeland A. L., Carrigan M. H. Exposure to negative affect cues and urge to smoke. *Exp Clin Psychopharmacol* 2012; **20**: 47–55.
137. Payne T. J., Schare M. L., Levis D. J., Colletti G. Exposure to smoking-relevant cues: Effects on desire to smoke and topographical components of smoking behaviour. *Addict Behav* 1991; **16**: 467–79.
138. Fucito L. M., Juliano L. M., Toll B. A. Cognitive reappraisal and expressive suppression emotion regulation strategies in cigarette smokers. *Nicotine Tob Res* 2010; **12**: 1156–61.
139. Hitsman B., Spring B., Pingitore R., Munafò M., Hedeker D. Effect of tryptophan depletion on the attentional salience of smoking cues. *Psychopharmacology (Berl)* 2007; **192**: 317–24.
140. Dennett D. C. *Content and Consciousness*. London, UK: Routledge; 2010.
141. Wiers R. W., Gladwin T. E., Hofmann W., Salemink E., Ridderinkhof K. R. Cognitive bias modification and cognitive control training in addiction and related psychopathology mechanisms, clinical perspectives, and ways forward. *Clin Psychol Sci* 2013; DOI: 10.1177/2167702612466547.
142. Rhodes J. D., Hawk L. W. Jr., Ashare R. L., Schlienz N. J., Mahoney M. C. The effects of varenicline on attention and inhibitory control among treatment-seeking smokers. *Psychopharmacology (Berl)* 2012; **223**: 131–8.
143. Mocking R. J., Patrick Pflanz C., Pringle A., Parsons E., McTavish S. E., Cowen P. J. *et al.* Effects of short-term varenicline administration on emotional and cognitive processing in healthy, non-smoking adults: a randomized, double-blind, study. *Neuropsychopharmacology* 2013; **38**: 476–84.
144. Patterson F., Jepson C., Strasser A. A., Loughead J., Perkins K. A., Gur R. C. *et al.* Varenicline improves mood and cognition during smoking abstinence. *Biol Psychiatry* 2009; **65**: 144–9.
145. Lerman C., Niaura R., Collins B. N., Wileyto P., Audrain-McGovern J., Pinto A. *et al.* Effect of bupropion on depression symptoms in a smoking cessation clinical trial. *Psychol Addict Behav* 2004; **18**: 362–6.
146. Catley D., Harris K. J., Okuyemi K. S., Mayo M. S., Pankey E., Ahluwalia J. S. The influence of depressive symptoms on smoking cessation among african americans an a randomized trial of bupropion. *Nicotine Tob Res* 2005; **7**: 859–70.
147. Niaura R., Britt D. M., Shadel W. G., Goldstein M., Abrams D., Brown R. Symptoms of depression and survival experience among three samples of smokers trying to quit. *Psychol Addict Behav* 2001; **15**: 13–17.
148. Piper M. E., Smith S. S., Schlam T. R., Fiore M. C., Jorenby D. E., Fraser D. *et al.* A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. *Arch Gen Psychiatry* 2009; **66**: 1253–62.
149. Smith S. S., McCarthy D. E., Japuntich S. J., Christiansen B., Piper M. E., Jorenby D. E. *et al.* Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. *Arch Intern Med* 2009; **169**: 2148–55.
150. Ebbert J. O., Hatsukami D. K., Croghan I. T., Schroeder D. R., Allen S. S., Hays J. T. *et al.* Combination varenicline and bupropion sr for tobacco-dependence treatment in cigarette smokers: a randomized trial. *JAMA* 2014; **311**: 155–63.
151. Brown R. A., Kahler C. W., Niaura R., Abrams D. B., Sales S. D., Ramsey S. E. *et al.* Cognitive-behavioral treatment for depression in smoking cessation. *J Consult Clin Psychol* 2001; **69**: 471–80.
152. Brown R. A., Niaura R., Lloyd-Richardson E. E., Strong D. R., Kahler C. W., Abrantes A. M. *et al.* Bupropion and cognitive-behavioral treatment for depression in smoking cessation. *Nicotine Tob Res* 2007; **9**: 721–30.
153. Gierisch J. M., Bastian L. A., Calhoun P. S., McDuffie J. R., Williams J. W. Jr. Smoking cessation interventions for patients with depression: a systematic review and meta-analysis. *J Gen Intern Med* 2012; **27**: 351–60.
154. van der Meer R. M., Willemsen M. C., Smit E., Cuijpers P. Smoking cessation interventions for smokers with current or past depression. *Cochrane Database Syst Rev* 2013; Issue 8. Art. No.: CD006102. DOI: 10.1002/14651858.CD006102.pub2.
155. Dimidjian S., Hollon S. D., Dobson K. S., Schmalting K. B., Kohlenberg R. J., Addis M. E. *et al.* Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. *J Consult Clin Psychol* 2006; **74**: 658–70.
156. MacPherson L., Tull M. T., Matusiewicz A. K., Rodman S., Strong D. R., Kahler C. W. *et al.* Randomized controlled trial of behavioral activation smoking cessation treatment for smokers with elevated depressive symptoms. *J Consult Clin Psychol* 2010; **78**: 55–61.
157. Kassel J. D., Stroud L. R., Paronis C. A. Smoking, stress, and negative affect: correlation, causation, and context across stages of smoking. *Psychol Bull* 2003; **129**: 270–304.
158. Brandon T. H. Negative affect as motivation to smoke. *Curr Dir Psychol Sci* 1994; **3**: 33–7.
159. Piper M. E., Rodock M., Cook J. W., Schlam T. R., Fiore M. C., Baker T. Psychiatric diagnoses among quitters versus continuing smokers 3 years after their quit day. *Drug Alcohol Depend* 2013; **128**: 148–54.
160. Hall F. S., Der-Avakian A., Gould T. J., Markou A., Shoaib M., Young J. W. Negative affective states and cognitive impairments in nicotine dependence. *Neurosci Biobehav Rev* 2015; **58**: 168–85.
161. McClave A. K., Dube S. R., Strine T. W., Kroenke K., Caraballo R. S., Mokdad A. H. Associations between smoking cessation and anxiety and depression among U.S. Adults. *Addict Behav* 2009; **34**: 491–7.
162. Mykletun A., Overland S., Aaro L. E., Liabo H. M., Stewart R. Smoking in relation to anxiety and depression: Evidence from a large population survey: the HUNT study. *Eur Psychiatry* 2008; **23**: 77–84.
163. Berg C. J., Wen H., Cummings J. R., Ahluwalia J. S., Druss B. G. Depression and substance abuse and dependency in relation to current smoking status and frequency of smoking among nondaily and daily smokers. *Am J Addict* 2013; **22**: 581–9.